Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis.
Saved in:
| Title: | Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. |
|---|---|
| Authors: | Tishina S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Dahlhaus A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Manik M; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Mulalic L; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Murr J; Translational Pancreatic Cancer Research Centre, TUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, TUM University Hospital, Technical University of Munich, Munich, Germany.; Centre for Organoid Systems (COS), Technical University Munich (TUM), Garching, Germany., Kotliar M; Cincinnati Children's Hospital Medical Center, Division of Allergy and Immunology, Cincinnati, OH, USA., Rakhsh-Khorshid H; University of Cologne, Faculty of Medicine and University Hospital Cologne, Centre for Biochemistry, Cologne, Germany., Kostopoulou M; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Hocher F; University of Kiel, Institute for Experimental Cancer Research, Kiel, Germany., Stroh J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Beck J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Williams RM; Fox Chase Cancer Center, Cancer Signaling and Microenvironment Program, Philadelphia, PA, USA., Balta GG; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Liu F; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Abdallah AT; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany., Bebber CM; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Reese M; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Lim JKM; Heinrich Heine University, Medical Faculty and University Hospital Düsseldorf, Institute of Neuropathology, Düsseldorf, Germany., Quaas A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Cologne, Germany., Brägelmann J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; University Hospital Cologne, Mildred Scheel School of Oncology, Cologne, Germany.; University Hospital Cologne, Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany., Pasparakis M; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; University Hospital Cologne, Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany.; University of Cologne, Institute for Genetics, Cologne, Germany., Beleggia F; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Balachandran S; Fox Chase Cancer Center, Cancer Signaling and Microenvironment Program, Philadelphia, PA, USA., Trauzold A; University of Kiel, Institute for Experimental Cancer Research, Kiel, Germany.; University Hospital Schleswig-Holstein (UKSH), Department of Gynecology and Obstetrics, Campus Kiel, Kiel, Germany., Liccardi G; University of Cologne, Faculty of Medicine and University Hospital Cologne, Centre for Biochemistry, Cologne, Germany., Astsaturov I; Fox Chase Cancer Center, Molecular Therapeutics Program, Philadelphia, PA, USA., Reichert M; Translational Pancreatic Cancer Research Centre, TUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, TUM University Hospital, Technical University of Munich, Munich, Germany.; Cincinnati Children's Hospital Medical Center, Division of Allergy and Immunology, Cincinnati, OH, USA.; German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and TUM University Hospital, Munich, Germany.; Bavarian Cancer Research Centre (BZKF), Munich, Germany., Androulidaki A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., von Karstedt S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany. s.vonkarstedt@uni-koeln.de.; CECAD Cluster of Excellence, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. s.vonkarstedt@uni-koeln.de.; University Hospital Cologne, Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany. s.vonkarstedt@uni-koeln.de. |
| Source: | Nature communications [Nat Commun] 2026 Jun 15; Vol. 17 (1). Date of Electronic Publication: 2026 Jun 15. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-026-73189-8 |
